The efficacy of immunizing with a combination of simian immunodeficiency virus (SIV) Nef vaccines was evaluated. Four vaccinates received three intradermal immunizations with recombinant vaccinia virus that expressed SIV Nef, followed by three intramuscular immunizations with rDNA also expressing SIV Nef. Finally, the four vaccinates received two subcutaneous boosts with recombinant SIV Nef protein. This immunization protocol elicited anti-Nef antibodies in all of the vaccinates as well as specific proliferative responses. However, specific cytotoxic T cell responses were not detected before virus challenge. All vaccinates were challenged intravenously with 10 MID(50) of SIVmacJ5 along with four controls. All eight subjects became infected after SIV challenge and there were no group-specific differences in virus load as measured by virus titration and vRNA analysis. The results of this study support indirectly the report from Gallimore and colleagues (Nat Med 1995;1:1667) suggesting that CD8(+) T lymphocyte responses are required for Nef-based vaccines to restrict SIV infection. If Nef-based vaccines are to be beneficial in controlling infection with immunodeficiency viruses, then it will be necessary to develop more effective immunization protocols that elicit potent CD8(+) cell responses reproducibly.

Download full-text PDF

Source
http://dx.doi.org/10.1089/08892220152644223DOI Listing

Publication Analysis

Top Keywords

siv nef
16
cell responses
12
specific proliferative
8
simian immunodeficiency
8
immunodeficiency virus
8
virus challenge
8
vaccinates received
8
nef-based vaccines
8
virus
7
siv
6

Similar Publications

Acute-phase innate immune responses in SIVmac239-infected Indian rhesus macaques may contribute to the establishment of elite control.

Front Immunol

November 2024

Department of Immunology, Center for Innate Immunity and Immune Disease, School of Medicine, University of Washington, Seattle, WA, United States.

Article Synopsis
  • The study investigates the spontaneous control of HIV/SIV viremia and its association with specific MHC class I allotypes, emphasizing the importance of CD8+ cytotoxic T lymphocytes (CTLs) for managing viral loads.
  • Researchers aimed to understand the factors contributing to a phenotype known as elite controllers (ECs) by vaccinating rhesus macaques and analyzing immune responses after infection.
  • Results showed that while vaccination did not prevent infection, it led to lower viral levels in vaccinated macaques, and 81% of them achieved elite control, highlighting differences in immune gene expression between vaccinated and unvaccinated groups.
View Article and Find Full Text PDF

SERINC5 is a restriction factor that becomes incorporated into nascent retroviral particles, impairing their ability to infect target cells. In turn, retroviruses have evolved countermeasures against SERINC5. For instance, the primate lentiviruses (HIV and SIV) use Nef, Moloney Murine Leukemia Virus (MLV) uses GlycoGag, and Equine Infectious Anemia Virus (EIAV) uses S2 to remove SERINC5 from the plasma membrane, preventing its incorporation into progeny virions.

View Article and Find Full Text PDF

A common feature of the mammalian (family ) is an RNA genome that contains an extremely high frequency of adenine (31.7-38.2%) while being extremely poor in cytosine (13.

View Article and Find Full Text PDF

Nef is an accessory protein unique to the primate HIV-1, HIV-2, and SIV lentiviruses. During infection, Nef functions by interacting with multiple host proteins within infected cells to evade the immune response and enhance virion infectivity. Notably, Nef can counter immune regulators such as CD4 and MHC-I, as well as the SERINC5 restriction factor in infected cells.

View Article and Find Full Text PDF

Vaccine strategies aimed at eliciting human immunodeficiency virus (HIV)-specific CD8 T cells are one major target of interest in HIV functional cure strategies. We hypothesized that CD8 T cells elicited by therapeutic vaccination during antiretroviral therapy (ART) would be recalled and boosted by treatment with the interleukin 15 (IL-15) superagonist N-803 after ART discontinuation. We intravenously immunized four simian immunodeficiency virus-positive (SIV) Mauritian cynomolgus macaques receiving ART with vesicular stomatitis virus (VSV), modified vaccinia virus Ankara strain (MVA), and recombinant adenovirus serotype 5 (rAd-5) vectors all expressing SIVmac239 Gag.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!